enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust cash runway into 2027, supporting continued operations and potential approval without immediate fundraising concerns. Despite reliance on a single indication, the risk/reward profile is attractive, with potential for 100% upside if approval is achieved. Eoneren/E+ via Getty Images Topline Summary And Update I have written twice on bladder cancer-focused enGene Holdings Inc. ( ENGN both times with substantial optimism about the investment thesis relative to their then-current market valuation. For the most part, 2025 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving c
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]Yahoo! Finance
- A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]Seeking Alpha
- A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Analyst Actions
- 9/10/25 - HC Wainwright
IBRX
Sec Filings
- 11/10/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- IBRX's page on the SEC website